Baseline patient characteristics.
| Apremilast, n = 34 | MTX, n = 15 | bDMARD, n = 101 | |
|---|---|---|---|
| Age, yrs | 55.7 (12.6), n = 33 | 61.5 (16.6), n = 15 | 52.9 (11.5), n = 99 |
| Female, n (%) | 20 (58.8), n = 34 | 10 (71.4), n = 14 | 59 (59.0), n = 100 |
| BMI, kg/m2 | 34.4 (9.3), n = 34 | 30.6 (8.1), n = 14 | 32.7 (6.8), n = 96 |
| Obesea, n (%) | 22 (64.7), n = 34 | 8 (57.1), n = 14 | 58 (60.4), n = 96 |
| Duration since PsA diagnosis, yrs | 8.0 (6.7), n = 33 | 5.4 (7.8), n = 14 | 9.7 (9.4), n = 96 |
| Prior non-bDMARD use, n (%) | 23 (67.6), n = 34 | 2 (13.3), n = 15 | 73 (72.3), n = 101 |
| Prior biologic use (≥ 1), n (%) | 27 (79.4), n = 34 | 3 (20.0), n = 15 | 76 (75.2), n = 101 |
| SJCb (0–66) | 1.5 (1.5), n = 34 | 1.0 (1.1), n = 15 | 0.8 (1.3), n = 101 |
| SJC > 1, n (%) | 17 (50.0), n = 34 | 4 (26.7), n = 15 | 26 (25.7), n = 101 |
| TJC (0–68) | 2.7 (3.9), n = 34 | 2.5 (3.3), n = 15 | 3.1 (5.9), n = 101 |
| TJC > 1, n (%) | 17 (50.0), n = 34 | 8 (53.3), n = 15 | 39 (38.6), n = 101 |
| SPARCC enthesitis > 0, n (%) | 6.0 (17.6) | 2.0 (13.3) | 20 (19.8) |
| Dactylitis count > 0, n (%) | 6.0 (17.6) | 2.0 (13.3) | 6.0 (5.9) |
| Axial disease, n (%) | 6 (17.6) | 3 (20.0) | 22 (21.8) |
| MDA, n (%) | 6 (20.0), n = 30 | 4 (36.4), n = 11 | 35 (37.2), n = 94 |
| VLDA, n (%) | 3 (10.0), n = 30 | 1 (9.1), n = 11 | 7 (7.4), n = 94 |
| cDAPSA score (0–154) | 14.0 (8.5), n = 34 | 11.5 (4.9), n = 11 | 12.3 (9.1), n = 98 |
| cDAPSA category, n (%) | |||
| Remission (≤ 4) | 5 (14.7), n = 34 | 1 (9.1), n = 11 | 17 (17.3), n = 98 |
| Low disease activity (> 4 to ≤ 13) | 12 (35.3), n = 34 | 7 (63.6), n = 11 | 45 (45.9), n = 98 |
| Moderate disease activity (>13 to ≤ 27) | 14 (41.2), n = 34 | 3 (27.3), n = 11 | 30 (30.6), n = 98 |
| High disease activity (> 27) | 3 (8.8), n = 34 | 0 (0.0), n = 11 | 6 (6.1), n = 98 |
| PtGA-PsA VAS score (0–100 mm) | 47.1 (29.8), n = 34 | 32.5 (26.3), n = 13 | 42.9 (27.7), n = 99 |
| Patient-reported overall pain VAS score (0–100 mm) | 50.5 (31.1), n = 34 | 46.7 (26.5), n = 14 | 42.7 (29.6), n = 99 |
| Patient-reported fatigue VAS score (0–100 mm) | 55.9 (30.0), n = 34 | 37.8 (31.9), n = 15 | 41.2 (29.0), n = 101 |
| HAQ-DI score | 1.0 (0.7), n = 34 | 0.5 (0.4), n = 14 | 0.7 (0.6), n = 100 |
| HAQ-DI score > 0.5, n (%) | 21 (61.8), n = 34 | 6 (42.9), n = 14 | 45 (45.0), n = 100 |
| Psoriasis-affected BSA, % | 7.1 (17.6), n = 30 | 4.8 (9.4), n = 14 | 4.1 (7.8), n = 97 |
| PtGA-PsO VAS score (0–100 mm) | 47.1 (29.4), n = 34 | 28.4 (16.6), n = 12 | 41.2 (26.8), n = 99 |
| Presence of physician-reported nail psoriasis, n (%) | 8 (23.5), n = 34 | 3 (20.0), n = 15 | 25 (24.8), n = 101 |
Values are expressed as mean (SD) unless otherwise indicated.
↵a BMI ≥ 30 kg/m2.
↵b Patients had oligoarticular PsA, defined as ≤ 4 swollen joints. bDMARD: biologic disease-modifying antirheumatic drug; BSA: body surface area; cDAPSA: Clinical Disease Activity Index for Psoriatic Arthritis; HAQ-DI: Health Assessment Questionnaire-Disability Index; MDA: minimal disease activity; MTX: methotrexate; PtGA-PsA: patient global assessment of disease activity-arthritis ; PtGA-PsO : patient global assessment of disease activity-arthritis and psoriasis; PsA: psoriatic arthritis; SJC: swollen joint count; SPARCC: Spondyloarthritis Research Consortium of Canada; TJC: tender joint count; VAS: visual analog scale; VLDA: very low disease activity.